Patents by Inventor Tal Zaks

Tal Zaks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230233474
    Abstract: The disclosure features methods for treating solid tumor malignancies and lymphomas by administering LNP encapsulated mRNAs encoding human OX40L, IL-23 and IL-36? polypeptides alone or in combination with checkpoint blockade. The disclosure also features compositions for use in the methods.
    Type: Application
    Filed: May 28, 2021
    Publication date: July 27, 2023
    Inventors: Robert MEEHAN, Tal ZAKS, Pamela COHEN
  • Publication number: 20230020362
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: May 5, 2022
    Publication date: January 19, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Publication number: 20220378904
    Abstract: Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 1, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
  • Publication number: 20220370354
    Abstract: This disclosure relates to mRNA therapy for the treatment of methylmalonic acidemia (MMA). mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase (MUT). mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.
    Type: Application
    Filed: May 8, 2020
    Publication date: November 24, 2022
    Inventors: Tal Zaks, Kelly Lindert, Lin Tung Guey
  • Publication number: 20220347292
    Abstract: Aspects of the invention relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines comprising hCMV antigenic polypeptides gH, gL, UL128, UL130, UL131 A and gB formulated in lipid nanoparticles, wherein the antigen-specific immune response to hCMV results in neutralizing antibodies that have i) a geometric mean titer of at least 3-fold against epithelial cell infection or ii) a geometric mean ratio of 9-41 against epithelial cell infection or iii) a geometric mean ratio of 4-8-fold against fibroblast infection.
    Type: Application
    Filed: September 11, 2020
    Publication date: November 3, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Lori Panther, Shinu John, Tal Zaks
  • Publication number: 20220323482
    Abstract: The disclosure features methods of treatment comprising systemic administration of mRNA encoding a therapeutic protein and delivered by lipid nanoparticle to human subjects.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 13, 2022
    Inventors: Allison AUGUST, Tal ZAKS, Stephen G. HOGE
  • Publication number: 20220257746
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Application
    Filed: February 1, 2022
    Publication date: August 18, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
  • Patent number: 11364292
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: June 21, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Patent number: 11351242
    Abstract: Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: June 7, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
  • Publication number: 20220152178
    Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
    Type: Application
    Filed: December 17, 2021
    Publication date: May 19, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Nicholas Valiante, Tal Zaks
  • Patent number: 11278611
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: March 22, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
  • Patent number: 11235052
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: February 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
  • Publication number: 20200368344
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: June 10, 2020
    Publication date: November 26, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Publication number: 20200368343
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: June 10, 2020
    Publication date: November 26, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
  • Publication number: 20200360481
    Abstract: The disclosure features methods for treating solid tumor malignancies and lymphomas by administering LNP encapsulated mRNAs encoding human OX40L, IL-23 and IL-36y polypeptides alone or in combination with checkpoint blockade. The disclosure also features compositions for use in the methods.
    Type: Application
    Filed: January 8, 2020
    Publication date: November 19, 2020
    Inventors: Robert MEEHAN, Tal ZAKS
  • Publication number: 20200289639
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Application
    Filed: April 21, 2020
    Publication date: September 17, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
  • Publication number: 20200289638
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Application
    Filed: April 16, 2020
    Publication date: September 17, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
  • Patent number: 10702597
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Patent number: 10675342
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 9, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
  • Patent number: 10517940
    Abstract: The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: December 31, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks